NCI Studying Biomarker Use in Lung Cancer

October 2008
Bioworld Week;10/13/2008, Vol. 16 Issue 41, p2
The article reports on the launching of a 1,200-patient clinical trial by the National Cancer Institute (NCI) in the U.S. The initiative aims to test whether biomakers can be used to predict the clinical benefits of Tarceva from Genentech Inc. and Alimta from Eli Lilly & Co. in patients with non-small-cell lung cancer (NSCLC). It reveals that Tarceva targets epidermal growth factor receptor (EGFR), whereas Alimta blocks tumor cell growth by another mechanism.


Related Articles

  • NCI Studying Biomarker Use in Lung Cancer Treatment. Young, Donna // BioWorld Today;10/6/2008, Vol. 19 Issue 194, p1 

    The article reports on a clinical trial launched by the U.S. National Cancer Institute (NCI) to test the use of biomarkers in the treatment of lung cancer. The trial will test whether biomarkers can be used to predict the clinical benefits of Tarceva (erlotinib) from Genentech Inc. and Alimta...

  • Tarceva Survival Near Alimta, But EGFR Data Offer the Real Upside. Morrison, Trista // BioWorld Today;8/4/2009, Vol. 20 Issue 148, p1 

    The article reports on the presentation of new overall survival data for Tarceva, an epidermal growth factor receptor (EGFR)-inhibitor from OSI Pharmaceuticals Inc. and partner Genentech Inc./Roche AG for lung cancer maintenance, at the 2009 World Conference on Lung Cancer. The significant...

  • NCI COLLABORATES WITH INSIGHT GENETICS.  // Biotech Business;May2013, Vol. 26 Issue 5, p3 

    The article reports on the collaboration between Tennessee-based diagnostic company Insight Genetics Inc. and the U.S. National Cancer Institute (NCI). It states that Insight has formulated an accurate diagnostic test to determine the response of patients with lung cancer to targeted therapies....

  • ELI LILLY & CO.  // MondayMorning;9/10/2012, Vol. 20 Issue 34, p1 

    The article reports that Eli Lilly & Co.'s drug regimen that included its Alimta therapy did not improve the survival of lung cancer patients in a late-stage clinical trial. According to the company, patients who were treated with a combination of Alimta, Avastin, and the chemotherapy drug...

  • KRAS mutations and cetuximab.  // Nature Reviews Cancer;Dec2008, Vol. 8 Issue 12, p909 

    The article offers news briefs related to clinical trials. An analysis of tumor samples from 394 patients with colorectal cancer has suggested that activating mutations in KRAS abolish the efficacy of the epidermal growth factor receptor inhibitor cetuximab. The U.S. National Cancer Institute...

  • (RESOURCES) Feds Look to Expand Access to Cancer Trials.  // Community Health Funding Week;5/6/2011, p20 

    The article informs that ways are being examined by the National Cancer Institute (NCI) to enable those with cancer and who do not have access to NCI-designated cancer centers to participate in various types of clinical trials, whose data will be used to improve prevention, screening and...

  • Clinical Development and Perspectives of CIMAvax EGF, Cuban Vaccine for Non-small-cell Lung Cancer Therapy. Rodríguez, Pedro C.; Rodríguez, Gryssell; González, Gisela; Lage, Agustín // MEDICC Review;Winter2010, Vol. 12 Issue 1, p17 

    Introduction CIMAvax EGF is a therapeutic anticancer vaccine developed entirely in Cuba and licensed in Cuba for use in adult patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). The vaccine is based on active immunotherapy by which an individual's immune response is manipulated to...

  • Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients. Wei Li; Fei Zhou; Caicun Zhou // OncoTargets & Therapy;2014, Vol. 7, p253 

    Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been demonstrated to improve responses and clinical outcomes significantly in patients with advanced non-small-cell lung cancer (NSCLC). In retrospective subgroup analyses of several studies, patients with Asian...

  • Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands. Verduyn, S. Cora; Biesma, Bonne; Schramel, Franz M. N. H.; van der Scheer, Feike W.; Langenfeld, Merel K.; de Peuter, Maria A.; Dingemans, Anne-Marie C. // Health & Quality of Life Outcomes;2012, Vol. 10 Issue 1, p108 

    Background: Gefitinib, a tyrosine kinase inhibitor, is an effective treatment in advanced non-small cell lung cancer (NSCLC) patients with an activating mutation in the epidermal growth factor receptor (EGFR). Randomised clinical trials showed a benefit in progression free survival for gefitinib...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics